CTLA4 and hepatocellular carcinoma: Considering this, some researchers have examined the adjustment of a combined dose of ICIs to mitigate treatment-related toxicities (grade ≥ 3 TRAEs, 19–53%), particularly reducing the dose of CTLA-4 Mab (grade ≥ 3 TRAEs, 34–37.8% in HCC; grade ≥ 3 TRAEs, 20% in colorectal cancer) [149, 150, 159].